FibroGen Stock Plunges Under Key Lines As Lead Drug Fails; Why Hope Isn't LostInvestors Business Daily • 06/07/23
FibroGen shares slide after Duchenne muscular dystrophy treatment falls short in trialMarket Watch • 06/07/23
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular DystrophyGlobeNewsWire • 06/07/23
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced AnemiaGlobeNewsWire • 05/18/23
FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)GlobeNewsWire • 05/05/23
FibroGen Announces Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical ValueGlobeNewsWire • 05/01/23
FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary FibrosisGlobeNewsWire • 04/03/23
FibroGen (FGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseZacks Investment Research • 02/20/23